• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Trends in Utilization of Urate-Lowering Therapies Following the US Food and Drug Administration's Boxed Warning on Febuxostat.美国食品药品监督管理局对非布司他发出黑框警告后降尿酸治疗的使用趋势
Arthritis Rheumatol. 2021 Mar;73(3):542-543. doi: 10.1002/art.41550. Epub 2021 Jan 27.
2
Interventions for tophi in gout.痛风石的治疗。
Cochrane Database Syst Rev. 2021 Aug 11;8(8):CD010069. doi: 10.1002/14651858.CD010069.pub3.
3
Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.降尿酸治疗对慢性痛风患者心血管影响的系统评价和荟萃分析。
Rheumatology (Oxford). 2017 Jul 1;56(7):1144-1153. doi: 10.1093/rheumatology/kex065.
4
Update on emerging urate-lowering therapies.新型降尿酸疗法的最新进展。
Curr Opin Rheumatol. 2009 Mar;21(2):143-9. doi: 10.1097/BOR.0b013e328325bd94.
5
Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.痛风患者的心血管疾病与降尿酸治疗的保护作用
Drugs. 2019 Apr;79(5):531-541. doi: 10.1007/s40265-019-01081-5.
6
New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.风湿学新视角：痛风伴心血管疾病患者中非布司他和别嘌醇心血管安全性的意义——New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial 和相关的美国食品药品监督管理局公共安全警示。
Arthritis Rheumatol. 2018 Nov;70(11):1702-1709. doi: 10.1002/art.40583.
7
The Challenges of Approaching and Managing Gout.痛风的诊治难点。
Rheum Dis Clin North Am. 2019 Feb;45(1):145-157. doi: 10.1016/j.rdc.2018.09.009.
8
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.慢性高尿酸血症治疗策略：基于循证的更新。
Medicina (Kaunas). 2021 Jan 10;57(1):58. doi: 10.3390/medicina57010058.
9
Treatment failure gout.痛风治疗失败
Med Health R I. 2009 Nov;92(11):369-71.
10
Advances in pharmacotherapy for the treatment of gout.痛风治疗的药物疗法进展
Expert Opin Pharmacother. 2015 Mar;16(4):533-46. doi: 10.1517/14656566.2015.997213. Epub 2014 Dec 30.

引用本文的文献

1
Meridian-Sinew Release Therapy as an adjunctive treatment for gouty arthritis: a systematic review and meta-analysis.经络-经筋松解疗法作为痛风性关节炎的辅助治疗：一项系统评价和荟萃分析。
J Orthop Surg Res. 2025 Aug 18;20(1):769. doi: 10.1186/s13018-025-06123-1.
2
Comparative risk of retinal microvascular disorders in patients with gout initiating febuxostat versus allopurinol: a population-based cohort study.痛风患者起始使用非布司他与别嘌醇后发生视网膜微血管病变的比较风险：一项基于人群的队列研究。
Sci Rep. 2025 Aug 7;15(1):28939. doi: 10.1038/s41598-025-00551-z.
3
Group-based trajectory modeling to assess adherence to chronic urate-lowering therapies among commercially insured US adults with gout.基于群组的轨迹建模，用于评估美国商业保险的痛风成年患者对慢性降尿酸治疗的依从性。
J Manag Care Spec Pharm. 2025 Aug;31(8):795-807. doi: 10.18553/jmcp.2025.31.8.795.
4
Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk.人类心血管疾病模型预测黄嘌呤氧化酶抑制剂的心血管风险。
PLoS One. 2023 Sep 8;18(9):e0291330. doi: 10.1371/journal.pone.0291330. eCollection 2023.
5
Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease : A Population-Based Cohort Study.别嘌醇起始治疗与伴发慢性肾脏病的痛风患者全因死亡率：一项基于人群的队列研究。
Ann Intern Med. 2022 Apr;175(4):461-470. doi: 10.7326/M21-2347. Epub 2022 Jan 25.
6
On the application of 3d metals for C-H activation toward bioactive compounds: The key step for the synthesis of silver bullets.3D金属在用于生物活性化合物的C-H活化方面的应用：合成“银弹”的关键步骤。
Beilstein J Org Chem. 2021 Jul 30;17:1849-1938. doi: 10.3762/bjoc.17.126. eCollection 2021.
7
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout.痛风、高尿酸血症及晶体相关性疾病网络（G-CAN）痛风的通用语言定义。
RMD Open. 2021 Apr;7(2). doi: 10.1136/rmdopen-2021-001623.
8
Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial.重新评估非布司他的心血管安全性：非布司他与别嘌醇简化试验的启示
Arthritis Rheumatol. 2021 May;73(5):721-724. doi: 10.1002/art.41638. Epub 2021 Mar 8.

本文引用的文献

1
2020 American College of Rheumatology Guideline for the Management of Gout.2020 年美国风湿病学会痛风管理指南。
Arthritis Rheumatol. 2020 Jun;72(6):879-895. doi: 10.1002/art.41247. Epub 2020 May 11.
2
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.当代美国痛风和高尿酸血症的流行情况及十年趋势：2007-2016 年国家健康和营养调查。
Arthritis Rheumatol. 2019 Jun;71(6):991-999. doi: 10.1002/art.40807. Epub 2019 Apr 15.
3
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.别嘌醇或非布司他治疗痛风患者的心血管安全性。
N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12.

Trends in Utilization of Urate-Lowering Therapies Following the US Food and Drug Administration's Boxed Warning on Febuxostat.

作者信息

Kim Seoyoung C, Neogi Tuhina, Kim Erin, Lii Joyce, Desai Rishi J

机构信息

Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

出版信息

Arthritis Rheumatol. 2021 Mar;73(3):542-543. doi: 10.1002/art.41550. Epub 2021 Jan 27.

DOI:10.1002/art.41550
PMID:33029931
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7914144/
Abstract
摘要